M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO PharmaphorumCardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated. Cardiovascular Read full story Post navigation Previous: Cardio biotech Kardigan binds off $400M upsized IPONext: New biotech cAMPfield emerges with $180M to reshape IBD treatment Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026